Search
Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigational[A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is … In February 2022, tepotinib was approved for use in Europe.[L42200]
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalPhiladelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein. … [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigational[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225]
Floxuridine
go.drugbank.com/drugs/DB00322ApprovedInvestigationalWhen administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. … It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Synonyms: 4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyc, 3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(Serdexmethylphenidate
go.drugbank.com/drugs/DB16629ApprovedAttention Deficit Hyperactivity Disorder (ADHD) is an early-onset neurodevelopmental disorder that often extends into adulthood and is characterized by developmentally inappropriate and impaired attention … [A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants
Fencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile. … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant.
Sulfasalazine
go.drugbank.com/drugs/DB00795ApprovedInvestigationalIt is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA). … is not FDA-recommmended for treatment of Crohn's disease.
Starch, corn
go.drugbank.com/drugs/DB11599ApprovedInvestigationalNutraceuticalStarch is the chief storage form of energy reserve (carbohydrates) in plants. … Corn starch may be added in some food products as a thickening agent or anti-caking agent, and is sometimes found in topical drugs as a skin protectant.
Categories: Compounds used in a research, industrial, or household setting